{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05410145",
            "orgStudyIdInfo": {
                "id": "D3S-001-100"
            },
            "secondaryIdInfos": [
                {
                    "id": "2023-508517-16",
                    "type": "EUDRACT_NUMBER"
                }
            ],
            "organization": {
                "fullName": "D3 Bio (Wuxi) Co., Ltd",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study of D3S 001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation",
            "officialTitle": "A Phase 1/2, Open Label, Dose-escalation, and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S 001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation"
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "D3 Bio (Wuxi) Co., Ltd",
                "class": "INDUSTRY"
            }
        },
        "descriptionModule": {
            "briefSummary": "This is a first-in-human (FIH), multicenter, open-label, dose-escalation, and dose-expansion Phase 1/2 clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of D3S-001 or combination therapy in subjects with advanced KRAS p.G12C mutant solid tumors. D3S-001 will be taken daily by oral administration in 21-day treatment cycles."
        },
        "conditionsModule": {
            "conditions": [
                "KRAS P.G12C"
            ],
            "keywords": [
                "KRAS p.G12C",
                "Mutation",
                "advanced solid tumors"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 392,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "D3S-001 monotherapy",
                    "type": "EXPERIMENTAL",
                    "description": "Part 1: Dose Escalation, D3S-001 administered orally.\n\nPart 2 and Part 3a Arm C: Dose Expansion, D3S-001 administered orally in selected cancer type patients.",
                    "interventionNames": [
                        "Drug: D3S-001"
                    ]
                },
                {
                    "label": "D3S-001 and pembrolizumab",
                    "type": "EXPERIMENTAL",
                    "description": "Part 3a Arm A: Dose Expansion, D3S-001 in combination therapy administered orally in selected cancer type patients.\n\nPembrolizumab administered intravenously.",
                    "interventionNames": [
                        "Drug: D3S-001",
                        "Drug: Pembrolizumab"
                    ]
                },
                {
                    "label": "D3S-001 and platinum doublet chemotherapy (cisplatin + pemetrexed or carboplatin + permetrexed)",
                    "type": "EXPERIMENTAL",
                    "description": "Part 3a Arm B: Dose Expansion, D3S-001 in combination therapy administered orally in selected cancer type patients.\n\nCisplatin + pemetrexed administered intravenously\n\nor\n\nCarboplatin + permetrexed administered intravenously",
                    "interventionNames": [
                        "Drug: D3S-001",
                        "Drug: Cisplatin",
                        "Drug: Carboplatin",
                        "Drug: Pemetrexed"
                    ]
                },
                {
                    "label": "D3S-001 and Cetuximab",
                    "type": "EXPERIMENTAL",
                    "description": "Part 3b: Dose Expansion, D3S-001 in combination therapy administered orally in selected cancer type patients.\n\nCetuximab administered intravenously.",
                    "interventionNames": [
                        "Drug: D3S-001",
                        "Drug: Cetuximab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "D3S-001",
                    "description": "Oral",
                    "armGroupLabels": [
                        "D3S-001 and Cetuximab",
                        "D3S-001 and pembrolizumab",
                        "D3S-001 and platinum doublet chemotherapy (cisplatin + pemetrexed or carboplatin + permetrexed)",
                        "D3S-001 monotherapy"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Pembrolizumab",
                    "description": "Intravenous",
                    "armGroupLabels": [
                        "D3S-001 and pembrolizumab"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Cisplatin",
                    "description": "Intravenous",
                    "armGroupLabels": [
                        "D3S-001 and platinum doublet chemotherapy (cisplatin + pemetrexed or carboplatin + permetrexed)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Carboplatin",
                    "description": "Intravenous",
                    "armGroupLabels": [
                        "D3S-001 and platinum doublet chemotherapy (cisplatin + pemetrexed or carboplatin + permetrexed)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Pemetrexed",
                    "description": "Intravenous",
                    "armGroupLabels": [
                        "D3S-001 and platinum doublet chemotherapy (cisplatin + pemetrexed or carboplatin + permetrexed)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Cetuximab",
                    "description": "Intravenous",
                    "armGroupLabels": [
                        "D3S-001 and Cetuximab"
                    ]
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion:\n\n* Subject must have a histologically or cytologically confirmed metastatic or locally advanced solid tumor which is progressing.\n* Subject must have documented KRAS p.G12C mutation identified within the last 5 years by a local test on tumor tissue or blood.\n* Subject must have measurable disease per RECIST v1.1.\n* Subject must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Subject must have adequate organ and marrow function within the screening period.\n\nExclusion:\n\n* Subject has any prior treatment with other treatments without adequate washout periods as defined in the protocol.\n* Subject has uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, uncontrolled or significant cardiovascular disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirements, substantially increase risk of incurring AEs, or compromise the ability of the subject to give written informed consent.\n* Subject has unresolved treatment-related toxicities from previous anticancer therapy of NCI CTCAE Grade \u22652 (with exception of vitiligo or alopecia).\n* Subject has active gastrointestinal disease or other that could interfere significantly with the absorption, distribution, metabolism, or excretion of oral therapy.\n* Concurrent participation in any clinical research study involving treatment with any investigational drug, radiotherapy, or surgery, except for the nontreatment phases of these studies (e.g., follow-up phase).\n\nOther protocol inclusion/exclusion criteria may apply",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Medical Director",
                    "role": "CONTACT",
                    "phone": "+86 21 61635900",
                    "email": "D3bio_CT@d3bio.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Cheng Chen, MD",
                    "affiliation": "D3 Bio (Wuxi) Co., Ltd",
                    "role": "STUDY_DIRECTOR"
                }
            ]
        }
    },
    "hasResults": false
}